Study is first to pinpoint the precise anatomical location where vision loss appears to occur in glaucoma

BALTIMORE, Jan. 3, 2011 /PRNewswire-USNewswire/ -- In a study published today in the Proceedings of the National Academy of Sciences (Early Edition ahead of print), a team of researchers from the Kennedy Krieger Institute and four collaborating institutions, identified a new and unexpected biological pathway that appears to contribute to the development of glaucoma and its resulting vision loss.

Prior research has suggested that the optic nerve head, the point where the cables that carry information from the eye to the brain first exit the eye, plays a role in glaucoma. In this study, researchers report a series of findings that offer novel insights into cellular and molecular mechanisms operating at the optic nerve head in two mouse models of glaucoma.  Most notably, they discovered that at a specific location within the optic nerve head, there is a unique class of cells called astrocytes that demonstrate properties that appear to make them a critical factor in the visual blinding that occurs in glaucoma.

Further, at this same site, researchers found abnormal forms of a protein called gamma synuclein that is similar to abnormal forms of alpha synuclein, a related protein known for its key role in cell loss in Parkinson's disease. The findings suggest that a biological process similar to Parkinson's disease unfolds in glaucoma at the specific anatomical location pinpointed in this study for the first time.

Finally, researchers discovered that at this anatomical location, there is a surprising process whereby astrocytes remove the debris of neurons, the cells that die in neurodegenerative disorders such as glaucoma. It is likely that this newly discovered process involving removal of the debris of one cell by a neighboring cell is important not only in glaucoma and Parkinson's disease, but also for many neurodegenerative diseases.

"These findings are very exciting because they give us several novel targets for future interventions," said Dr. Nicholas Marsh-Armstrong, senior study author and a research scientist at Kennedy Krieger Institute. "I believe these findings put us on the cusp of discovering a treatment for glaucoma that may also have relevance for a number of other neurodegenerative diseases."

Future studies will examine this novel pathway and molecular/cellular mechanism to understand precisely what steps go awry in glaucoma and what can be controlled pharmacologically to identify interventions that slow the disease progression.

Dr. Marsh-Armstrong and other scientists at Kennedy Krieger Institute collaborated on this study with colleagues at the Johns Hopkins University School of Medicine, University of California at San Diego, Cardiff University in England, and the University of Murcia in Spain.

This research was principally supported by the Melza M. and Frank Theodore Barr Foundation through the Glaucoma Research Foundation, with additional grant funding provided in part by the International Retinal Research Foundation and the National Eye Institute of the National Institutes of Health.

About Glaucoma

Glaucoma is a neurodegenerative disorder that causes blindness by damaging the optic nerve, which sends signals from the eye to the brain. It affects more than 60 million people and is the second leading cause of blindness worldwide. While older individuals are at higher risk for the disease, babies and children are also susceptible to glaucoma, especially those with certain neurological disorders.

About the Kennedy Krieger Institute

Internationally recognized for improving the lives of children and adolescents with disorders and injuries of the brain and spinal cord, the Kennedy Krieger Institute in Baltimore, MD serves more than 16,000 individuals each year through inpatient and outpatient clinics, home and community services and school-based programs.  Kennedy Krieger provides a wide range of services for children with developmental concerns mild to severe, and is home to a team of investigators who are contributing to the understanding of how disorders develop while pioneering new interventions and earlier diagnosis.  For more information on Kennedy Krieger Institute, visit www.kennedykrieger.org.  

About the Glaucoma Research Foundation

Located in San Francisco, the Glaucoma Research Foundation is the nation's most experienced foundation dedicated solely to glaucoma research and education. In addition to funding innovative research like the Catalyst For a Cure research consortium and its Shaffer Grants for Innovative Glaucoma Research, Glaucoma Research Foundation provides free education material, including the definitive reference for newly diagnosed patients, Understanding and Living with Glaucoma (available in both English and Spanish editions); brochures serving those at highest risk, including African-Americans and Latinos; and a toll free phone, 800-826-6693, staffed during office hours with an information specialist to answer questions about glaucoma.  For more information, please visit www.glaucoma.org.

SOURCE Kennedy Krieger Institute